Biotech is mainly news-driven, I'm sure you all kn
Post# of 72440
P P2b database lock - 55% run-up
P P2a final patient visit - 100% run-up
B-UP top-line result - 50% run-up
B-OM top-line result - 50% run-up
If shorts were in control, there wouldn't be any run-ups. Some will say why did the stock drop afterward? That's why I point to Aspire over and over again.
There are three popular explanations here for the current SP.
1. Naked shorting.
2. Constant dilutions.
3. Lack of cash.
Personally I believe in #2 & #3. If the SP doesn't move after a licensing deal is announced, then I'll admit #1 is correct.
Happy 4th to all and thank you for your service!